Bulletin
Investor Alert

ADC Therapeutics S.A.

NYS: ADCT

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
ADC Therapeutics S.A.

After Hours

 --Quotes are delayed by 20 min

Jun 30, 2022, 4:06 p.m.

ADCT
/zigman2/quotes/214411413/composite

$

7.71

Change

-0.24 -3.02%

Volume

Volume 211

Quotes are delayed by 20 min

/zigman2/quotes/214411413/composite

Previous close

$ 7.79

$ 7.95

Change

+0.16 +2.05%

Day low

Day high

$7.39

$7.95

Open

52 week low

52 week high

$5.52

$32.00

Open

Company Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, ca...

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Valuation

Price to Sales Ratio

45.71

Price to Book Ratio

9.34

Enterprise Value to EBITDA

-0.87

Enterprise Value to Sales

2.79

Efficiency

Total Asset Turnover

0.06

Liquidity

Current Ratio

7.10

Quick Ratio

6.95

Cash Ratio

6.31

Profitability

Gross Margin

88.29

Operating Margin

-770.57

Pretax Margin

-721.86

Net Margin

-678.20

Return on Assets

-40.65

Return on Equity

-91.72

Return on Total Capital

-69.11

Capital Structure

Total Debt to Total Assets

22.61

Officers and Executives

Name Age Officer Since Title
Mr. Ron Squarer 54 2020 Chairman
Mr. Ameet Mallik 49 2022 President & Chief Executive Officer
Ms. Jennifer Creel 49 2020 Chief Financial Officer
Dr. Joseph S. Camardo 66 - Head-Medical Affairs
Dr. Patrick van Berkel 51 2012 Senior Vice President-Research & Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/adct

MarketWatch News on ADCT

  1. ADC Therapeutics started at hold with $42 stock price target at Stifel Nicolaus

    9:00 a.m. Dec. 3, 2020

    - Tomi Kilgore

  2. ADC Therapeutics stock soars 56% in trading debut

    12:05 p.m. May 15, 2020

    - Ciara Linnane

  3. ADC Therapeutics stock soars 52% in trading debut

    12:02 p.m. May 15, 2020

    - Ciara Linnane

  6. ADC Therapeutics sets IPO terms to raise up to $185.3 million

    6:48 a.m. May 14, 2020

    - Tomi Kilgore

  8. ADC Therapeutics sets IPO terms, to offer 8.1 mln shares priced at $23 to $26 each

    7:13 a.m. Sept. 23, 2019

    - Ciara Linnane

/news/nonmarketwatch/company/us/adct

Other News on ADCT

  2. ADC Therapeutics (ADCT) Investor Presentation - Slideshow

    11:33 a.m. June 4, 2022

    - Seeking Alpha

  10. ADC Therapeutics SA (ADCT) Q4 2021 Earnings Call Transcript

    1:31 p.m. March 3, 2022

    - Motley Fool

  13. ADC Therapeutics SA (ADCT) Investor Presentation - Slideshow

    4:31 a.m. Feb. 11, 2022

    - Seeking Alpha

  15. Tracking Baker Brothers Portfolio - Q3 2021 Update

    11:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

ADC Therapeutics SA

Biopôle

Route de la Corniche 3B

Epalinges, Vaud 1066

Phone

41 2126530200

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$33.92M

Net Income

$-230.03M

Employees

312.00

Annual Report for ADCT

/news/pressrelease/company/us/adct

Press Releases on ADCT

  4. ADC Therapeutics to Present at the Jefferies Healthcare Conference

    7:15 a.m. June 1, 2022

    - BusinessWire - BZX

  6. ADC Therapeutics Announces CEO Transition

    7:00 a.m. May 9, 2022

    - BusinessWire - BZX

  17. ADC Therapeutics to Participate in Guggenheim Oncology Conference

    8:15 a.m. Feb. 2, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.